NCT01023958 - Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 19, 2009

Primary Completion Date

September 19, 2011

Study Completion Date

September 19, 2011

Conditions

Neoplasms

Interventions

DRUG

BI 6727, IV infusion

phase II

Trial Locations (21)

1230.2.5 Boehringer Ingelheim Investigational Site, Beverly Hills

1230.2.10 Boehringer Ingelheim Investigational Site, Los Angeles

1230.2.34 Boehringer Ingelheim Investigational Site, Miami

1230.2.29 Boehringer Ingelheim Investigational Site, Orlando

1230.2.6 Boehringer Ingelheim Investigational Site, Chicago

1230.2.17 Boehringer Ingelheim Investigational Site, Joliet

1230.2.24 Boehringer Ingelheim Investigational Site, Metairie

1230.2.1 Boehringer Ingelheim Investigational Site, Baltimore

1230.2.25 Boehringer Ingelheim Investigational Site, Las Vegas

1230.2.36 Boehringer Ingelheim Investigational Site, Las Vegas

1230.2.19 Boehringer Ingelheim Investigational Site, Lebanon

1230.2.20 Boehringer Ingelheim Investigational Site, New York

1230.2.23 Boehringer Ingelheim Investigational Site, New York

1230.2.12 Boehringer Ingelheim Investigational Site, Charlotte

1230.2.4 Boehringer Ingelheim Investigational Site, Philadelphia

1230.2.38 Boehringer Ingelheim Investigational Site, Beaumont

1230.2.41 Boehringer Ingelheim Investigational Site, Tyler

1230.2.43 Boehringer Ingelheim Investigational Site, Webster

1230.2.44 Boehringer Ingelheim Investigational Site, Fairfax

1230.2.51 Boehringer Ingelheim Investigational Site, Tainan City

1230.2.50 Boehringer Ingelheim Investigational Site, Taipei